News for BLCM Stock

Bellicum Discontinues Phase 1/2 Trials and Initiates Evaluation of Strategic Alternatives Bellicum Presents Early Phase 1 Results for BPX-601 in Prostate Cancer at ASCO GU Cancers Symposium CORRECTION -- Bellicum Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Bellicum Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Bellicum Pharmaceuticals to Present Early Phase 1 Results for BPX-601 in Prostate Cancer at ASCO 2023 Genitourinary Cancers Symposium Bellicum Announces Presentation by UNC at ASH 2022 on Potential Abrogation of iC9 CAR T-Cell Toxicities with Rimiducid Bellicum Reports Third Quarter 2022 Financial Results and Provides Operational Update Bellicum Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Bellicum Pharmaceuticals to Participate in the 2022 Cell & Gene Meeting on the Mesa Bellicum Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Bellicum Pharmaceuticals to Participate in the H.C. Wainwright 24th Annual Global Investment Conference Bellicum Reports Second Quarter 2022 Financial Results and Provides Operational Update Bellicum Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Bellicum Reports First Quarter 2022 Financial Results and Provides Operational Update Bellicum Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Bellicum Reports Fourth Quarter 2021 Financial Results and Provides Operational Update Bellicum Pharmaceuticals to Participate in the B. Riley Securities 2022 Virtual Oncology Conference Bellicum Regains Compliance with Nasdaq Continued Listing Requirements Bellicum Announces Positive Interim Data from Phase 1/2 GoCAR-T® Studies, Secures $35 Million Private Placement Equity Financing Priced at Market Bellicum Reports Third Quarter 2021 Financial Results and Provides Operational Update Bellicum Pharmaceuticals to Participate in the H.C. Wainwright 23rd Annual Global Investment Conference Bellicum and MD Anderson Announce Additional License Agreement for Use of CaspaCIDe® Safety Switch Bellicum Reports Second Quarter 2021 Financial Results and Provides Operational Update Bellicum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Bellicum Enters License Agreement with UNC Lineberger and Mass General for Use of CaspaCIDe® Safety Switch Bellicum Reports First Quarter 2021 Financial Results and Provides Operational Update Bellicum Reports Fourth Quarter 2020 Financial Results and Provides Operational Update Bellicum to Report Fourth Quarter and Full Year 2020 Financial Results and Provide Corporate Update Bellicum Announces First Reported Use of CaspaCIDe® Safety Switch to Mitigate CAR-T Cell Toxicity Ponce Therapeutics Inc. Commences First R & D Program in Anti-Aging Products for Skin Bellicum Reports FDA Lifted Clinical Hold on BPX-601 Phase 1/2 Clinical Trial Bellicum Enrolls First Patient in Phase 1/2 Clinical Trial for BPX-603 Bellicum Reports Clinical Hold Placed on BPX-601 Phase 1/2 Clinical Trial Bellicum Reports Third Quarter 2020 Financial Results and Provides Operational Update Bellicum Pharmaceuticals Announces Closing of $25.0 Million Underwritten Offering Bellicum Announces $25.0 Million Underwritten Offering Priced At-The-Market Bellicum Announces Interim BPX-601 Data and Corporate Restructuring Bellicum to Participate in Two Upcoming Virtual Investor Conferences Bellicum Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Bellicum Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Bellicum Receives FDA IND Clearance to Initiate a Phase 1/2 Clinical Trial for BPX-603, a Dual-Switch GoCAR-T® for HER2+ Solid Tumors Bellicum to Participate in Two Upcoming Virtual Investor Conferences Bellicum to Report Second Quarter 2020 Financial Results and Provide Corporate Update Bellicum Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Bellicum Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)